Infliximab "TNF-alpha antagonist" decreases intraabdominal adhesions.
OBJECTIVE
To evaluate the effect of infliximab on adhesion formation and it's associated morbidity and complications.


METHODS
This study was performed in the Faculty of Medicine, Gazi University, Turkey between July 2005 and October 2005. Thirty-five rats were randomly divided into 4 groups. Laparotomy was performed in the Sham group (n=5), whereas cecal abrasion was carried out in all other groups. After cecal abrasion 0.9% sodium chloride was administered in the saline group (n=10), infliximab was administered to the study group (n=10) and nothing was administered to the last group (n=10). Adhesion formation was evaluated with macroscopic and microscopic adhesion scoring systems. Peritoneal fluid samples and mesenteric lymph node biopsies were taken to rule out bacterial peritonitis. Blood and peritoneal irrigation fluid samples were taken to measure the Tumor necrosis factor-alpha (TNF-alpha) levels.


RESULTS
Macroscopic adhesion scores showed fewer adhesions in the infliximab group. The infliximab group had significantly fewer adhesions than the abrasion control and saline groups. According to the histological findings, there were no statistically significant differences between the groups.


CONCLUSIONS
Early blocking of the activity of TNF-alpha after cecal abrasion resulted in lower rates of adhesion formation, macroscopically. The TNF-alpha, a proinflammatory cytokine appears to be an important mediator for postoperative adhesion formation.
Kurukahvecioglu
Osman
O
Faculty of Medicine, Gazi Universitesi Tip Fakultesi, Genel Cerrahi Anabilim Dali Besevler, Ankara, Turkey. okurukahveci@yahoo.com
Koksal
Hande
H
Gulbahar
Ozlem
O
Erdem
Ozlem
O
Engin
Doruk
D
Yazicioglu
Omer
O
Kerem
Mustafa
M
Taneri
Ferit
F
D034861:Abdominal Wall / Q000473:pathology / Q000601:surgery*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D010532:Peritoneal Diseases / Q000209:etiology / Q000517:prevention & control*; D011183:Postoperative Complications; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab